Early-phase clinical trials evaluating buparlisib (a PI3K inhibitor) in solid tumors provide translational relevance to this approach, demonstrating a reduction in metabolic resilience in cancers with highly active NRF2 [35]. Here, NFE2L2 is linked to cancer.